¿ Aviron Inc., of Mountain View, Calif., sold 142,205 shares to Acqua Wellington North American Equities Fund Ltd., of New York, and received notice that the FDA accepted its FluMist biologics license application for review, triggering a $15.5 million milestone payment from marketing partner Wyeth Lederle Vaccines, a division of Wyeth-Ayerst Laboratories, in turn a division of American Home Products Corp., of Madison, N.J. The equity sale is the third valued at $8 million to Acqua Wellington since the beginning of November. Proceeds from the placement will be used to fund operations and regulatory approval, manufacturing and commercialization costs associated with FluMist, the company's intranasal influenza vaccine. The BLA for Flumist was filed in October. (See BioWorld Today, Dec. 1, 2000, and Nov. 1, 2000.)
¿ Incyte Genomics Inc., of Palo Alto, Calif., completed its $77 million acquisition of Proteome Inc., of Beverly, Mass. The proteomics database company will continue operations in Massachusetts. (See BioWorld Today, Dec. 22, 2000.)
¿ Ortec International Inc., of New York, said the clinical data from its pivotal trial of Composite Cultured Skin for facilitating wound closure of split thickness skin donor site wounds in burn patients showed statistically significant results for its primary endpoint. The trial was designed to evaluate the Composite Cultured Skin's ability to effect 100 percent wound closure. Use of CSS in the trial accelerated wound closure and the time to readiness to recrop, or reharvest, donor skin by an average of six days (p<0.002). Ortec will use the data to support the submission of a premarket approval application.
¿ Paradigm Genetics Inc., of Research Triangle Park, N.C., licensed the Rosetta Resolver Expression Data Analysis System from Rosetta Inpharmatics Inc., of Kirkland, Wash. The Resolver is distributed by Agilent Technologies Inc., of Palo Alto, Calif. Financial details were unavailable.
¿ Praecis Pharmaceuticals Inc., of Cambridge, Mass., submitted an investigational new drug application to the FDA to initiate Phase I testing of Apan, its Alzheimer's therapeutic. Apan is designed to inhibit the aggregation of beta-amyloid, and has proven efficacious in preclinical testing.